Levokarnil Evalar, 300 mg/ml, 100 ml, flak.

Method of administration and dosage The preparation is used as part of complex therapy. Orally 30 minutes before meals, additionally diluting with liquid. To measure doses, use the dropper plug or the measuring cup included in the packaging. For dosing convenience, a pipette or medical syringe can also be used. Adults and children over 12 years old During prolonged physical and psycho-emotional stress: from 0.75 g (2.5 ml) 3 times a day to 2.25 g (7.5 ml) 2-3 times a day. In nervous anorexia, as well as during the rehabilitation period after illnesses and surgical interventions and injuries: 1.5 g (5 ml) 2 times a day. Treatment course – for 1-2 months. In complex therapy of chronic gastritis and chronic pancreatitis with reduced secretory function: 0.375 g (1.25 ml) 2 times a day. Treatment course – for 1-1.5 months. For the treatment of skin diseases: 0.75 g (2.5 ml). Treatment course – for 2-4 weeks. In mild hyperthyroidism: 0.25 g (13 drops) 2-3 times a day. Treatment course – 20 days. The treatment course is repeated after a 1-2 month break or prescribed for 3 months without a break. In vascular, toxic, and traumatic brain lesions: 0.75 g (2.5 ml) per day. Treatment course – for 3-5 days. If necessary, a repeat course is prescribed after 12-14 days. In diseases accompanied by carnitine deficiency (primary and secondary carnitine deficiency): up to 50-100 mg/kg (2-5 drops/kg) of body weight per day, divided into 2-3 doses. Treatment course – for 3-4 months. For children, it is prescribed as an additive to sweet dishes (kisel, compote, juices). The use of the preparation in children under 3 years old is carried out under medical supervision. For children under 3 years old, the dose is determined by the attending physician. According to clinical studies, the recommended dose of levocarnitine for children under 3 years old is 50-100 mg/kg (2-5 drops/kg) of body weight per day, divided into 2-3 doses. From 3 to 6 years – in a single dose of 0.1 g (5 drops) 2-3 times a day, in a daily dose of 0.2-0.3 g (11-16 drops). Treatment course – 1 month. For children from 6 to 12 years old, it is prescribed in a single dose of 0.2-0.3 g (11-16 drops) 2-3 times a day, in a daily dose of 0.4-0.9 g (22-48 drops). Treatment course – at least 1 month. In case of growth retardation: 0.25 g (13 drops) 2-3 times a day. Treatment course – 20 days. The treatment course is repeated after a 1-2 month break or prescribed for 3 months without a break. In sports medicine and during intensive training: 2.5 g (8.33 ml) 1-3 times a day (daily dose 2.5-7.5 g); if used for therapeutic purposes – 70-100 mg/kg/day (5-7.5 g/day). Intake courses: 3-4 weeks in the pre-competition period. During the training process – up to 6-8 weeks. Side effect Undesirable reactions are listed in accordance with organ and system damage and frequency of occurrence. Frequency of occurrence is defined as follows: very common (≥1/10), common (from ≥1/100 to <1/10), uncommon (from ≥1/1 000 to <1/100), rare (from ≥1/10 000 to <1/1 000), very rare (<1/10 000), frequency unknown (cannot be estimated based on available data). Gastrointestinal disorders**: frequency unknown – nausea, vomiting, abdominal pain, diarrhea. With these manifestations, discontinuation of the preparation is not required. Musculoskeletal and connective tissue disorders: frequency unknown – myasthenia (in patients with uremia). Skin and subcutaneous tissue disorders*: frequency unknown – skin rash, hives, facial edema, facial hyperemia. General disorders and administration site reactions: frequency unknown – unusual body odor ("fishy body odor")**. *If these symptoms occur, it is necessary to discontinue the medicinal product and consult a doctor. **Dose reduction may reduce or eliminate the unusual body odor ("fishy body odor") and gastrointestinal symptoms associated with taking the medicinal product. Tolerance should be carefully monitored during the first week of intake and after any dose increase. Overdose Symptoms: dyspeptic disorders, myasthenic disorders (in patients with uremia). Treatment: gastric lavage, intake of activated charcoal. Use during pregnancy and breastfeeding The use of the preparation Levokarnil® during pregnancy and breastfeeding is not recommended due to the lack of sufficient experience in this category of patients. Interaction with other medicinal products Glucocorticosteroids promote the accumulation of the preparation in tissues (except the liver), other anabolics enhance the effect. Special instructions Treatment of children under 3 years of age should be carried out under medical supervision. Excipients The preparation Levokarnil® contains methylparahydroxybenzoate and propylparahydroxybenzoate, which may cause allergic reactions (possibly delayed). Influence on the ability to drive vehicles, mechanisms The preparation does not affect the performance of potentially dangerous types of activities requiring special attention and quick reactions (driving a car and other vehicles, working with moving mechanisms, dispatcher and operator work, etc.). Form of release Solution for oral administration 300 mg/ml. 50 ml in brown or orange glass vials for medicinal products, sealed with dropper plugs and screw caps with first-opening control. 100 ml in brown or orange glass vials for medicinal products, sealed with dropper plugs and screw caps with first-opening control or screw caps with a sealing element and first-opening control. Each vial together with the instructions for use is placed in a cardboard pack. It is allowed to include a measuring cup in the cardboard pack. Storage conditions At a temperature not exceeding 25 °C.